SCHEMBL5380728

SCHEMBL5380728

COC(=O)c1cc(S(=O)(=O)Nc2ccc(OCc3ccc(F)cc3Cl)cc2)ccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.56
ADAMTS5 Q9UNA0 3/20 0.56
ADAMTS4 O75173 2/20 0.56
MMP2 P08253 2/20 0.56
MMP14 P50281 2/20 0.56
SMN1; SMN2 Q16637 1/20 0.52
POLB P06746 1/20 0.51
MMP1 P03956 5/20 0.49
AR P10275 1/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ADAM17 P78536 2/20 0.44
TNF P01375 1/20 0.44
MMP3 P08254 1/20 0.44
MMP9 P14780 1/20 0.44
MMP8 P22894 1/20 0.44
ADAMTS1 Q9UHI8 1/20 0.44
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367846 0.92 POLB (0.60) MMP13ADAMTS5ADAMTS4MMP2MMP14
SCHEMBL5380794 0.84 SMN1; SMN2 (0.58) MMP2MMP14SMN1; SMN2POLBAR
SCHEMBL5376964 0.84 POLB (0.45) SMN1; SMN2POLBALDH1A1LMNAGAA
SCHEMBL5376620 0.82 SMN1; SMN2 (0.53) SMN1; SMN2POLBARALDH1A1MEN1
SCHEMBL14434486 0.81 CXCR2 (0.45) MMP13ADAMTS5ADAMTS4MMP2MMP14
SCHEMBL5378800 0.80 SMN1; SMN2 (0.60) SMN1; SMN2POLBARALDH1A1MEN1
SCHEMBL5369902 0.80 SMN1; SMN2 (0.55) SMN1; SMN2POLBARALDH1A1MEN1
SCHEMBL5376600 0.78 MMP2 (0.55) MMP2MMP14SMN1; SMN2POLBMMP1
SCHEMBL5376792 0.77 SMN1; SMN2 (0.59) SMN1; SMN2POLBARALDH1A1LMNA
SCHEMBL5373265 0.77 KMT2A (0.64) SMN1; SMN2POLBARTNFMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD MMP13 3079/4885ADAMTS5 4155/4885ADAMTS4 4338/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD MMP13 3256/4885ADAMTS5 4248/4885ADAMTS4 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.